Healthy Returns: Eli Lilly, other drugmakers show off encouraging weight loss drug data
Publishing timestamp: 2024-06-26 11:37:13
Summary
Drugmakers presented encouraging data on weight loss and diabetes drugs at the American Diabetes Association's annual meeting. Companies are focusing on new approaches to treat metabolic diseases, including GLP-1s. Highlights include Eli Lilly's Zepbound helping resolve sleep apnea, Novo Nordisk's positive results on semaglutide, Zealand Pharma's weight loss injection, Altimmune's obesity drug, Viking Therapeutics' experimental drugs, and Gilead's oral GLP-1. Oracle also introduced an AI-powered tool to help doctors with documentation, saving time and improving accuracy.
Sentiment: POSITIVE
Tickers: VKTX, GILD, LLY, NOVO.B-DK, ORCL, ZEAL-DK, ALT,
Keywords: zealand pharma a/s, oracle corp, orlando, eli lilly and co, gilead sciences inc, science, altimmune inc, health care industry, business news, biotech and pharmaceuticals, viking therapeutics inc, novo nordisk a/s,